Amorphous-state characterization of efavirenz-polymer hot-melt extrusion systems for dissolution enhancement

Journal of Pharmaceutical Sciences

Volumn 101, Issue 9, 2012, Pages 3456-3464

  Sathigari, Sateesh Kumar ^a   Radhakrishnan, Vinod K ^b   Davis, Virginia A ^b   Parsons, Daniel L ^a   Babu, R Jayachandra ^a  

^a AUBURN UNIVERSITY   (United States)

^b AUBURN UNIVERSITY   (United States)

Author keywords

Amorphous; Dissolution rate; Extrusion; Solid dispersion; Solid state stability; Solubility

Indexed keywords

EFAVIRENZ; EUDRAGIT; EUDRAGIT EPO; POVIDONE DERIVATIVE; POVIDONE S 630; UNCLASSIFIED DRUG;

ARTICLE; CHEMICAL INTERACTION; CONTROLLED STUDY; CRYSTALLIZATION; DIFFERENTIAL SCANNING CALORIMETRY; DISPERSION; DRUG FORMULATION; DRUG SOLUBILITY; DRUG STORAGE; FLOW KINETICS; FOURIER TRANSFORM MASS SPECTROMETRY; HOT MELT EXTRUSION; MISCIBILITY; PHARMACOLOGICAL PROCEDURES; SOLID STATE; THERMODYNAMICS; VISCOSITY; X RAY DIFFRACTION;

EID: 84864048513     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23125     Document Type: Article

References (33)

1. Maurin MB, Rowe SM, Blom K, Pierce ME. 2002. Kinetics and mechanism of hydrolysis of efavirenz. Pharm Res 19(4):517-522.
2. Chiappetta DA, Hocht C, Sosnik A. 2002. A highly concentrated and taste-improved aqueous formulation of efavirenz for a more appropriate pediatric management of the anti-HIV therapy. Curr HIV Res 8(3):223-231.
3. Gazzard B, Bernard AJ, Boffito M, Churchill D, Edwards S, Fisher N, Geretti AM, Johnson M, Leen C, Peters B, Pozniak A, Ross J, Walsh J, Wilkins E, Youle M. 2006. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. HIV Med 7(8):487-503.
4. Kasim NA, Whitehouse M, Ramachandran C, Bermejo M, Lennernas H, Hussain AS, Junginger HE, Stavchansky SA, Midha KK, Shah VP, Amidon GL. 2004. Molecular properties of WHO essential drugs and provisional biopharmaceutical classification. Mol Pharm 1(1):85-96.
5. Takano R, Sugano K, Higashida A, Hayashi Y, Machida M, Aso Y, Yamashita S. 2006. Oral absorption of poorly water-soluble drugs: Computer simulation of fraction absorbed in humans from a miniscale dissolution test. Pharm Res 23(6):1144-1156.
6. Sosnik A, Chiappetta DA, Carcaboso AM. 2009. Drug delivery systems in HIV pharmacotherapy: What has been done and the challenges standing ahead. J Control Release 138(1):2-15.
7. Vasconcelos T, Sarmento B, Costa P. 2007. Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs. Drug Discov Today 12(23-24):1068-1075.
8. Kaplan S. 1972. Biopharmaceutical considerations in drug formulation design and evaluation. Drug Metab Rev 1:15-34.
9. Sathigari S, Chadha G, Lee YH, Wright N, Parsons DL, Rangari VK, Fasina O, Babu RJ. 2009. Physicochemical characterization of efavirenz-cyclodextrin inclusion complexes. AAPS PharmSciTech 10(1):81-87.
10. Crowley MM, Zhang F, Repka MA, Thumma S, Upadhye SB, Battu SK, McGinity JW, Martin C. 2007. Pharmaceutical applications of hot-melt extrusion: Part I. Drug Dev Ind Pharm 33(9):909-926.
11. Chokshi RJ, Zia H, Sandhu HK, Shah NH, Malick WA. 2007. Improving the dissolution rate of poorly water soluble drug by solid dispersion and solid solution: Pros and cons. Drug Deliv 14(1):33-45.
12. Yang J, Grey K, Doney J. 2010. An improved kinetics approach to describe the physical stability of amorphous solid dispersions. Int J Pharm 384(1-2):24-31.
13. Hancock BC, Zografi G. 1997. Characteristics and significance of the amorphous state in pharmaceutical systems. J Pharm Sci 86(1):1-12.
14. Konno H, Taylor LS. 2006. Influence of different polymers on the crystallization tendency of molecularly dispersed amorphous felodipine. J Pharm Sci 95(12):2692-2705.
15. Leuner C, Dressman J. 2000. Improving drug solubility for oral delivery using solid dispersions. Eur J Pharm Biopharm 50(1):47-60.
16. Serajuddin AT. 1999. Solid dispersion of poorly water-soluble drugs: Early promises, subsequent problems, and recent breakthroughs. J Pharm Sci 88(10):1058-1066.
17. Janssens S, Van den Mooter G. 2009. Review: Physical chemistry of solid dispersions. J Pharm Pharmacol 61(12):1571-1586.
18. Marsac PJ, Shamblin SL, Taylor LS. 2006. Theoretical and practical approaches for prediction of drug-polymer miscibility and solubility. Pharm Res 23(10):2417-2426.
19. Matsumoto T, Zografi G. 1999. Physical properties of solid molecular dispersions of indomethacin with poly(vinylpyrrolidone) and poly(vinylpyrrolidone-co-vinyl-acetate) in relation to indomethacin crystallization. Pharm Res 16(11):1722-1728.
20. Chokshi RJ, Sandhu HK, Iyer RM, Shah NH, Malick AW, Zia H. 2005. Characterization of physico-mechanical properties of indomethacin and polymers to assess their suitability for hot-melt extrusion processs as a means to manufacture solid dispersion/solution. J Pharm Sci 94(11):2463-2474.
21. Kappelhoff BS, Rosing H, Huitema ADR, Beijnen JH. 2003. Simple and rapid method for the simultaneous determination of the non-nucleoside reverse transcriptase inhibitors efavirenz and nevirapine in human plasma using liquid chromatography. J Chromatogr B 792(2):353-362.
22. Greenhalgh DJ, Williams AC, Timmins P, York P. 1999. Solubility parameters as predictors of miscibility in solid dispersions. J Pharm Sci 88(11):1182-1190.
23. DiNunzio JC, Miller DA, Yang W, McGinity JW, Williams RO, 3rd. 2008. Amorphous compositions using concentration enhancing polymers for improved bioavailability of itraconazole. Mol Pharm 5(6):968-980.
24. Mura P, Faucci MT, Manderioli A, Furlanetto S, Pinzauti S. 1998. Thermal analysis as a screening technique in preformulation studies of picotamide solid dosage forms. Drug Dev Ind Pharm 24(8):747-756.
25. Gordon M, Taylor JS. 1952. Ideal copolymers and the second order transitions of synthetic rubbers. I. Non-crystalline polymers. J Appl Chem 2:493-500.
26. Gupta P, Bansal AK. 2005. Molecular interactions in celecoxib-PVP-meglumine amorphous system. J Pharm Pharmacol 57(3):303-310.
27. Babu RJ, Brostow W, Kalogeras IM, Sathigari S. 2009. Glass transitions in binary drug + polymer systems. Materials Lett 63(30):2666-2668.
28. Rumondor AC, Marsac PJ, Stanford LA, Taylor LS. 2009. Phase behavior of poly(vinylpyrrolidone) containing amorphous solid dispersions in the presence of moisture. Mol Pharm 6(5):1492-1505.
29. Hancock BC, Parks M. 2000. What is the true solubility advantage for amorphous pharmaceuticals? Pharm Res 17(4):397-404.
30. Shah B, Kakumanu VK, Bansal AK. 2006. Analytical techniques for quantification of amorphous/crystalline phases in pharmaceutical solids. J Pharm Sci 95(8):1641-1665.
31. Albers J, Alles R, Matthee K, Knop K, Nahrup JS, Kleinebudde P. 2009. Mechanism of drug release from polymethacrylate-based extrudates and milled strands prepared by hot-melt extrusion. Eur J Pharm Biopharm 71(2):387-394.
32. Six K, Verreck G, Peeters J, Brewster M, Van Den Mooter G. 2004. Increased physical stability and improved dissolution properties of itraconazole, a class II drug, by solid dispersions that combine fast- and slow-dissolving polymers. J Pharm Sci 93(1):124-131.
33. Craig DQ, Royall PG, Kett VL, Hopton ML. 1999. The relevance of the amorphous state to pharmaceutical dosage forms: Glassy drugs and freeze dried systems. Int J Pharm 179(2):179-207.